Key result
Beta-blockers linked to ~25% fewer weekly anginal episodes and better exercise tolerance versus CCBs.
Why the study?
Beta-blockers and calcium channel blockers are widely used for symptom control in chronic stable angina, but their comparative effectiveness remains an area of clinical interest.
Does beta-blocker monotherapy improve symptom control and exercise tolerance compared to calcium channel blocker monotherapy in patients with chronic stable angina?
Observational (n=260)
No
Does beta-blocker monotherapy improve symptom control and exercise tolerance compared to calcium channel blocker monotherapy in patients with chronic stable angina?
In an observational cohort of patients with chronic stable angina, beta-blocker monotherapy was associated with superior symptom control, heart rate reduction, and exercise tolerance compared to calcium channel blockers.
May favor beta-blockers over calcium channel blockers for rate control in stable angina; leaves open effects on symptoms and outcomes pending randomized trials.
Background: Chronic stable angina is a common manifestation of coronary artery disease that significantly affects quality of life. Beta-blockers and calcium channel blockers are widely used for symptom control; however, their comparative effectiveness remains an area of clinical interest. Objective: This study aimed to compare the effectiveness of beta-blockers and calcium channel blockers in the management of chronic stable angina in terms of symptom control, exercise tolerance, and clinical outcomes. Methodology: This comparative observational study was conducted at the Department of Cardiology, Punjab Institute of Cardiology, Lahore, Pakistan, from June 2025 to December 2025, and included 260 patients diagnosed with chronic stable angina. Results: The mean age of the participants was 61.5 ± 9.3 years, with 148 (56.9%) males and 112 (43.1%) females. Beta-blockers achieved better heart rate control compared with calcium channel blockers (68.2 ± 7.5 bpm vs 74.6 ± 8.1 bpm, p < 0.001), with a greater proportion of patients achieving controlled heart rate (92 (70.8%) vs 54 (41.5%)). Patients receiving beta-blockers experienced fewer anginal episodes (2.1 ± 1.3 vs 2.8 ± 1.5, p = 0.002) and lower nitrate use (1.6 ± 1.1 vs 2.3 ± 1.4, p = 0.001). Exercise tolerance was also higher in the beta-blocker group (6.8 ± 1.4 metabolic equivalents (METs) vs 6.1 ± 1.6 METs, p = 0.003). Overall symptom improvement was greater with beta-blockers (72.5 ± 12.6% vs 65.3 ± 13.8%, p = 0.001), along with fewer hospital visits (1.4 ± 0.8 vs 1.9 ± 1.1, p = 0.002) and higher patient satisfaction scores (8.4 ± 1.1 vs 7.8 ± 1.3, p = 0.004). Conclusion: Beta-blockers demonstrated superior outcomes compared with calcium channel blockers in controlling symptoms and improving functional capacity in patients with chronic stable angina.
No takes yet. Share an insight, caveat, or question.
Rehman et al. (2026) conducted an observational in Chronic stable angina (n=260). Beta-blockers vs. Calcium channel blockers was evaluated on Anginal episodes per week (p=0.002). Beta-blockers reduced anginal episodes per week (2.1 vs 2.8) and improved exercise tolerance compared to calcium channel blockers in patients with chronic stable angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: